Axiom Investors LLC DE Has $500,000 Holdings in United Therapeutics Corporation $UTHR

Key Points

• Axiom Investors LLC DE has significantly reduced its stake in United Therapeutics Corporation by 83.9%, leaving it with 1,621 shares valued at approximately $500,000.
• Despite missing analysts' earnings estimates for the last quarter, United Therapeutics reported a year-over-year revenue increase of 11.7%, reaching $798.6 million.
• Several analysts have recently raised their price targets for United Therapeutics, with Oppenheimer's new target at $575.00, reflecting positive market sentiment.

Axiom Investors LLC DE cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 83.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,621 shares of the biotechnology company's stock after selling 8,419 shares during the quarter. Axiom Investors LLC DE's holdings in United Therapeutics were worth $500,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of UTHR. SVB Wealth LLC acquired a new stake in United Therapeutics during the 1st quarter worth about $32,000. Sound Income Strategies LLC acquired a new stake in United Therapeutics during the 1st quarter worth about $49,000. Brooklyn Investment Group boosted its position in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 98 shares during the period. WPG Advisers LLC acquired a new stake in United Therapeutics during the 1st quarter worth about $60,000. Finally, State of Wyoming acquired a new stake in United Therapeutics during the 4th quarter worth about $62,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $394.62 on Tuesday. The stock's 50 day simple moving average is $309.83 and its 200 day simple moving average is $305.60. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $436.95. The company has a market capitalization of $17.80 billion, a price-to-earnings ratio of 15.40, a PEG ratio of 6.11 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the business posted $5.85 earnings per share. The firm's revenue was up 11.7% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday. Jefferies Financial Group raised their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Bank of America raised their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company raised their price target on United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research note on Wednesday, September 3rd. Finally, Morgan Stanley cut their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $429.62.

Insider Buying and Selling

In related news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 106,181 shares of company stock valued at $35,537,239 over the last 90 days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.